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Palbociclib treatment alters nucleotide 
biosynthesis and glutamine dependency 
in A549 cells
Lindsey R. Conroy1,7, Pawel Lorkiewicz2,3, Liqing He3, Xinmin Yin3, Xiang Zhang3,6, Shesh N. Rai4,5,6 
and Brian F. Clem1,6* 
Abstract 
Background: Aberrant activity of cell cycle proteins is one of the key somatic events in non-small cell lung cancer 
(NSCLC) pathogenesis. In most NSCLC cases, the retinoblastoma protein tumor suppressor (RB) becomes inactivated 
via constitutive phosphorylation by cyclin dependent kinase (CDK) 4/6, leading to uncontrolled cell proliferation. Pal-
bociclib, a small molecule inhibitor of CDK4/6, has shown anti-tumor activity in vitro and in vivo, with recent studies 
demonstrating a functional role for palbociclib in reprogramming cellular metabolism. While palbociclib has shown 
efficacy in preclinical models of NSCLC, the metabolic consequences of CDK4/6 inhibition in this context are largely 
unknown.
Methods: In our study, we used a combination of stable isotope resolved metabolomics using [U-13C]-glucose and 
multiple in vitro metabolic assays, to interrogate the metabolic perturbations induced by palbociclib in A549 lung 
adenocarcinoma cells. Specifically, we assessed changes in glycolytic activity, the pentose phosphate pathway (PPP), 
and glutamine utilization. We performed these studies following palbociclib treatment with simultaneous silencing of 
RB1 to define the pRB-dependent changes in metabolism.
Results: Our studies revealed palbociclib does not affect glycolytic activity in A549 cells but decreases glucose 
metabolism through the PPP. This is in part via reducing activity of glucose 6-phosphate dehydrogenase, the rate 
limiting enzyme in the PPP. Additionally, palbociclib enhances glutaminolysis to maintain mitochondrial respiration 
and sensitizes A549 cells to the glutaminase inhibitor, CB-839. Notably, the effects of palbociclib on both the PPP and 
glutamine utilization occur in an RB-dependent manner.
Conclusions: Together, our data define the metabolic impact of palbociclib treatment in A549 cells and may support 
the targeting CDK4/6 inhibition in combination with glutaminase inhibitors in NSCLC patients with RB-proficient 
tumors.
Keywords: RB, Palbociclib, Metabolism, Glutaminolysis, PPP, Lung cancer
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Background
Lung cancer is among the most frequently diagnosed 
cancers and is the leading cause of cancer-related death 
worldwide, with an estimated 1.6 million deaths each 
year [1–3]. Of its subtypes, non-small cell lung cancer 
(NSCLC) accounts for 85% of all lung cancer diagnoses 
[2]. One of the hallmark events in NSCLC pathogenesis is 
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deregulation of the cell cycle [4, 5]. Transition from G1 to 
S phase during cell cycle progression is tightly regulated 
by phosphorylation of the retinoblastoma protein tumor 
suppressor (RB) by the cyclin dependent kinase (CDK) 
4/6-Cyclin D complex. Activity of the CDK4/6-Cyclin 
D complex is strongly inhibited by p16 which induces 
cell cycle arrest. In the majority of NSCLC cases, p16 is 
mutated, deleted, or epigenetically silenced, resulting in 
constitutive phosphorylation of RB and uncontrolled cell 
cycle progression [4, 5]. Pharmacologically, CDK4/6 inhi-
bition phenocopies p16 activity [6, 7].
Highly selective and potent small-molecule CDK4/6 
inhibitors have shown anti-tumor activity both in  vitro 
and in  vivo [6, 7]. Among these inhibitors, palbociclib 
(PD-0332991) has been FDA-approved for the treat-
ment of women with breast cancer [8]. Recently, palbo-
ciclib has shown efficacy either alone or as combination 
therapy in preclinical studies of NSCLC [9–13]. Mecha-
nistically, the functional consequences of CDK4/6 inhi-
bition apart from cell cycle arrest in NSCLC are largely 
unknown; yet, metabolic reprogramming in response to 
palbociclib has revealed unique targetable vulnerabilities 
in several cancers including pancreatic, colorectal, and 
leukemia [14–16]. As such, we aimed to characterize the 
metabolic phenotype induced by palbociclib in NSCLC.
Herein, we report that palbociclib treatment decreases 
nucleotide biosynthesis and increases glutamine utiliza-
tion without altering glycolysis in A549 lung adenocar-
cinoma cells. Specifically, palbociclib-induced glutamine 
dependency sensitizes A549 cells to glutaminase inhi-
bition. Together, these data expand our knowledge of 
understanding of the metabolic consequences of CDK4/6 
inhibition in NSCLC.
Methods
Cell culture
The A549 lung adenocarcinoma cells were obtained 
from ATCC and cultured in DMEM (Gibco, Cat. No. 
11965126) supplemented with 10% fetal bovine serum 
(Gibco, Cat. No. 10438034) and 50μg/mL gentamicin sul-
fate (Gibco, Cat. No. 15750-078). Cells were maintained 
at 5%  CO2 at 37  °C. Palbociclib (PD-0332991) (Cat. No. 
S1116) and CB-839 (Cat. No. S7655) were purchased 
from Selleck Chemicals.
Cell transfections
Using Lipofectamine RNAiMAX reagent (Invitrogen, 
Cat. No. 13778150), A549 cells were transiently trans-
fected with control siRNA (Ambion, Silencer Select Neg-
ative Control #2, Cat. No. 4390826) or siRNA targeted to 
RB1 (Ambion, Silencer Select s523, Cat. No. 4390824) for 
24 h prior to palbociclib treatment.
Cell proliferation and viability
A549 cells were seeded at 120,000 in 6-well plates (Corn-
ing, Cat. No. 3516), followed by transfection and treat-
ment with 1  μM palbociclib or vehicle control. For 
glutaminase inhibition studies, cells were seeded at 
25,000 in 24-well plates (Corning, Cat. No. 3526), fol-
lowed by 25  nM CB-839 treatment. Forty-eight hours 
post-treatment, cell number was determined by Trypan 
Blue (Gibco, Cat. No. 15250-061) exclusion and enumer-
ation using a hemocytometer.
Glucose uptake
A549 cells were seeded at 120,000 in 6-well plates (Corn-
ing, Cat. No. 3516). Cells were transfected and treated 
with 1 μM palbociclib or vehicle control for 48 h prior to 
performing the assay. Cells were then incubated in glu-
cose-free DMEM (Gibco, Cat. No. 11966-025) for 30 min, 
followed by incubation with 5 μL of 2-[14C]-deoxyglucose 
(0.25  μCi/mL; Perkin Elmer, Cat. No. NEC720A050UC) 
and three subsequent washes with ice-cold glucose-free 
DMEM. Lysates were collected in 500 μL of 0.1% SDS and 
scintillation counts (counts/min) were measured using 
350 μL of cell lysate on a Tri-Carb 2910 liquid scintilla-
tion analyzer (Perkin Elmer Life Sciences). Protein con-
centration was determined using the BCA assay (Pierce, 
Cat. No. 23225) according to the manufacturer’s proto-
col. Counts were normalized to μg of protein.
Glycolysis stress test
A549 cells were seeded at 120,000 in 6-well plates (Corn-
ing, Cat. No. 3516). Cells were transfected and treated 
with 1 μM palbociclib or vehicle control for 48 or 120 h 
prior to performing the assay. ECAR measurements were 
conducted using a Seahorse XFe96 analyzer according 
to manufacturer’s protocol. One day prior to perform-
ing the assay, cells were reseeded at 35,000 in XFe96 cell 
culture plates and incubated 5%  CO2 at 37 °C. One hour 
prior to analysis, growth medium was replaced with assay 
medium (DMEM minus phenol red and sodium bicar-
bonate (Corning, Cat. No. 90-013-PB) that is supple-
mented with 2 mM l-glutamine, pH 7.4) and incubated 
in a non-CO2 incubator. During the assay, 10  mM glu-
cose (Sigma, Cat. No. G8270), 1 μM oligomycin (Sigma, 
Cat. No. 495455), and 50  mM 2-deoxyglucose (Sigma, 
Cat. No. D8375) were sequentially injected into each well 
in accordance with standard protocols. Absolute rates 
(mpH/min) were normalized to μg of protein.
Mito stress test
A549 cells were seeded at 120,000 in 6-well plates (Corn-
ing, Cat. No. 3516). Cells were transfected and treated 
with 1  μM palbociclib or vehicle control for 48  h prior 
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to performing the assay. OCR measurements were con-
ducted using a Seahorse XFe96 analyzer according to 
manufacturer’s protocol. One day prior to performing 
the assay, cells were reseeded at 35,000 in XFe96 cell cul-
ture plates and incubated in 5%  CO2 at 37 °C. One hour 
prior to analysis, growth medium was replaced with assay 
medium (DMEM minus phenol red and sodium bicarbo-
nate (Corning, Cat. No. 90-013-PB) that is supplemented 
with 1  mM pyruvate, 2  mM  l-glutamine, and 10  mM 
glucose, pH 7.4) and incubated in a non-CO2 incubator. 
During assay, 1 μM oligomycin (Sigma, Cat. No. 495455), 
2  μM FCCP (Sigma, Cat. No. C2920), and 1  μM rote-
none/antimycin A (Sigma Cat. No. R8875 and A8674) 
were sequentially injected into each well in accordance 
with standard protocols. Absolute rates (p moles/min) 
were normalized to μg of protein.
Mito fuel flexibility assay
A549 cells were seeded at 120,000 in 6-well plates (Corn-
ing, Cat. No. 3516). Cells were transfected and treated 
with 1  μM palbociclib or vehicle control for 48  h prior 
to performing the assay. OCR measurements were con-
ducted using a Seahorse XFe96 analyzer according to 
manufacturer’s protocol. One day prior to performing 
the assay, cells were reseeded at 35,000 in XFe96 cell 
culture plates and incubated 5%  CO2 at 37 °C. One hour 
prior to analysis, growth medium was replaced with assay 
medium (DMEM minus phenol red and sodium bicarbo-
nate (Corning, Cat. No. 90-013-PB) that is supplemented 
with 1  mM pyruvate, 2  mM  l-glutamine, and 10  mM 
glucose, pH 7.4) and incubated in a non-CO2 incubator. 
Capacity and dependency for fatty acid, glutamine, and 
glucose oxidation were determined through injections of 
the following inhibitors in accordance with standard pro-
tocols: 4 μM etomoxir (Sigma, Cat. No. E1905) (inhibits 
long chain fatty acid oxidation), 3  μM BPTES (Sigma, 
Cat. No. SML0601) (inhibits glutamine oxidation), and 
2 μM UK5099 (Sigma, Cat. No. PZ0160) (inhibits glucose 
oxidation). The percent capacity for each fuel source was 
determined by dividing the observed OCR under inhi-
bition of the two other pathways by the OCR observed 
when all pathways are inhibited. The percent dependency 
for each fuel source was determined by dividing the OCR 
observed when that specific pathway is inhibited by the 
OCR observed when all pathways are inhibited. Absolute 
rates (p moles/min) were normalized to μg of protein.
Glucose 6‑phosphate dehydrogenase activity assay
A549 cells were seeded at 120,000 in 6-well plates (Corn-
ing, Cat. No. 3516). Cells were transfected and treated 
with 1  μM palbociclib or vehicle control for 48  h prior 
to performing the assay. The activity of G6PD from 
cell lysates was measured following the manufacturer’s 
protocol using the Glucose-6-Phosphate Dehydrogenase 
Activity Assay Kit (Sigma, Cat. No. MAK015-1KT) and 
normalized to μg of protein.
[U‑13C]‑glucose tracer studies
Cells were seeded at 1 × 106 cells in 10  cm dishes 
(Corning, Cat. No. 430167) and treated with pal-
bociclib or vehicle control for 48  h. Cells were then 
labeled for 6  h with DMEM supplemented with 1  g/L 
[U-13C]-glucose (Sigma, Cat. No. 38974) and 10% dia-
lyzed fetal bovine serum (Gibco, Cat. No. A3382001). 
Cells were washed three times in ice-cold 1× PBS and 
quenched with acetonitrile. Metabolites were extracted 
in acetonitrile:water:chloroform (2  mL:1  mL:740  µL). 
Samples were centrifuged at 3000×g for 20  min at 
4  °C to separate the polar, lipid, and cell debris lay-
ers. The remaining cell debris was re-extracted with 
500  µL chloroform:methanol:butylated hydroxytoluene 
(2:1:1  mM) and centrifuged at 22,000×g for 20  min at 
4  °C. The residual polar and lipid fractions were com-
bined with their respective fractions from the first 
extraction. The polar fraction was vacuum-dried by lyo-
philization. The dried sample was dissolved in 100  µL 
50% acetonitrile and vigorously vortex-mixed for 3 min. 
After centrifugation at 14,000 rpm and 4  °C for 20 min, 
80  µL of supernatant was collected for 2DLC-MS/MS 
analysis.
2DLC‑MS/MS analysis and data processing
All samples were analyzed in a random order on a 
Thermo Q Exactive HF Hybrid Quadrupole-Orbitrap 
Mass Spectrometer coupled with a Thermo DIONEX 
UltiMate 3000 HPLC system (Thermo Fisher Scientific, 
Waltham, MA, USA). The UltiMate 3000 HPLC system 
was equipped with a reverse phase chromatography 
(RPC) column and a hydrophilic interaction chroma-
tography (HILIC) column that were configured in par-
allel to form a parallel 2DLC-MS system [17]. To obtain 
full MS data, every sample was analyzed by the parallel 
2DLC-MS in positive mode (+) and negative mode (−), 
respectively. For metabolite identification, one unlabeled 
sample in each sample group was analyzed by 2DLC-
MS/MS in positive mode (+) and negative mode (−) to 
acquire MS/MS spectra at three collision energies (20, 40 
and 60 eV).
Data analysis for 2DLC‑MS/MS
Full MS.raw files were first converted to.mzML format 
with msConvert tool, a part of an open-source Prote-
oWizard suite, described in detail by Adusumilli and 
Mallick [18]. Isotopologue peak deconvolution and 
assignments were performed using El-MAVEN (Eluci-
data) [19]. Peaks were assigned using a metabolite list 
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generated and verified using full scan MS and MS/MS 
spectra of unlabeled samples, as described previously 
[20–22]. The metabolite list contained metabolite names 
and corresponding molecular formulae used to gener-
ate theoretical m/z values for all possible isotopologues, 
and retention times for each metabolite. El-MAVEN 
parameters for compound library matching were as fol-
lows: EIC Extraction Window ± 7 ppm; Match Retention 
Time ± 0.60  min. For 13C isotopologue peak detection, 
the software criteria were set as follows: Minimum Iso-
tope-parent correlation 0.20; Isotope is within 5 scans 
of parent; Abundance threshold 1.0; Maximum Error To 
Natural Abundance 100%. All assignments were visually 
inspected and compared to unlabeled samples for refer-
ence. The peak list with corresponding abundances was 
exported to a comma-separated (CSV) file and uploaded 
to the Polly workflow (Elucidata) for natural abundance 
correction and calculation of total pool size for each 
metabolite (by summing peak areas of each detected 
isotopologue) using Polly Isocorrect module. Finally, the 
data were downloaded and plotted using Microsoft Excel 
and GraphPad Prism software.
Real time‑PCR
Total RNA was isolated from cell pellets using the RNe-
asy Mini Kit (Qiagen, Cat. No. 74104) according to the 
manufacturer’s protocol. The resulting total RNA (1μg) 
was converted to cDNA using the High-Capacity RNA-to 
cDNA kit (Applied Biosystems, Cat. No. 4387406). Gene 
expression was determined by qPCR using the following 
Taqman Gene Expression Assays: RB1 (Hs01078066_
m1), RRM1 (Hs01040698_m1), RRM2 (Hs00357247_
g1), PRPS2 (Hs00267624_m1), G6PD (Hs0166169_m1), 
ASCT2 (Hs01056542_m1), GLS (Hs01014020_m1), and 
GLUD1 (Hs01632647_g1). β-actin (Hs01060665_g1) was 
used as an internal control. Data are reported as the log 
(base 2) of the fold change with respect to siNeg treated 
with vehicle control.
Immunoblotting
Whole-cell lysates were prepared in RIPA lysis buffer 
(Pierce, Cat. No. 89900) containing protease and phos-
phatase inhibitors. 20 μg of protein was separated on 
10% Bolt Bis–Tris gels (Invitrogen, Cat. No. nw00102box) 
and transferred to PVDF membrane. Membranes were 
blocked with 5% BSA (Fisher Bioreagents, Cat. No. 
BP1600-100) in TBS-T and probed with 1:1000 dilution 
of anti-phospho-Rb (Cell Signaling, #3590S) overnight 
at 4  °C. Membranes were washed and incubated with 
HRP-conjugated anti-rabbit (1:5000) secondary antibod-
ies (Invitrogen, Cat. No. 32260) for 1 h. Protein detection 
was performed by ECL chemiluminescent reagent (GE 
Healthcare Amersham, Cat. No. RPN2232) exposure. 
1:20,000 dilution of anti-β-actin antibody (Sigma, A2228) 
was used to assess protein loading.
Statistical analysis
Statistical analyses were carried out using GraphPad 
Prism. As described in their respective figure legends, 
analyses were performed using student’s t-test and two-
way ANOVA with Sidak’s post hoc multiple comparisons. 
Within the two-factor ANOVA, interaction term was pri-
marily included in the analysis and was dropped if found 
not to be significant. Statistical significances between 
any two groups are as follows: *p < 0.05, **p < 0.01, and 
***p < 0.001.
Results
Palbociclib treatment does not alter glycolysis in A549 cells
To assess the role of CDK4/6 inhibition on metabolism 
in NSCLC, we utilized A549 lung adenocarcinoma cells. 
While these cells express wild-type RB, they harbor a 
 p16INK4A deletion that results in constitutive RB hyper-
phosphorylation and inactivation. Treatment with pal-
bociclib inhibits the phosphorylation of RB and results in 
decreased cell proliferation (Additional file 1: Figure S1A, 
B). Recent studies have demonstrated that palbociclib 
alters glucose metabolism in multiple cancer subtypes 
[23–25]. To monitor the effect of palbociclib on glucose 
uptake, we performed radiolabeled glucose uptake assay 
using 2-[14C]-deoxyglucose in A549 cells. As CDK4/6 
inhibition can have metabolic effects independent of RB, 
these studies were performed following palbociclib treat-
ment with simultaneous knockdown of RB1 (Additional 
file  1: Figure S2). We observed no significant change in 
glucose uptake upon palbociclib treatment in A549 cells 
(Fig. 1a). To assess glycolytic function in response to pal-
bociclib treatment, we performed a glycolysis stress test 
using the Seahorse XFe96 analyzer. Similar to glucose 
uptake, we observed no difference in the extracellular 
acidification rate (ECAR) upon palbociclib treatment 
(Fig. 1b–f), suggesting palbociclib does not alter glycoly-
sis in A549 cells.
To define global changes in glucose utilization result-
ing from palbociclib treatment, we performed [U-13C]-
glucose tracer studies. Utilization of ubiquitously labeled 
glucose results in the intracellular generation of 13C labe-
ling of the hexose and triose sugar intermediates within 
the glycolytic pathway; leading to fully labeled pyruvate 
(m + 3) and lactate (m + 3) (Fig. 2a) Palbociclib has been 
shown to increase glycolytic flux in both breast and pan-
creatic cancers [14, 24, 25]; however, consistent with our 
glycolysis stress test findings, palbociclib did not alter 
glucose carbon incorporation into glycolytic interme-
diates in A549 cells (Fig.  2b–g). Our data suggest that 
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the palbociclib-mediated effects on glycolysis may be 
tissue-specific.
CDK4/6 inhibition decreases glucose flux through the PPP
We then examined whether glucose metabolism within 
tangential pathways, such as the pentose phosphate path-
way, may be altered by palbociclib treatment. Metabolism 
of fully labeled 13C-glucose generates different metabolite 
labeling patterns within PPP intermediates, including the 
5-carbon labeled ribose moiety (m + 5) on de novo syn-
thesized nucleotides from ribose-5-phosphate as well as 
7 labeled carbon sedoheptulose-7-phosphate (m + 7). 
We observed decreased m + 5 isotopologue labeling of 
several nucleotides (Fig.  3a) as well as diminished glu-
cose carbon incorporation into sedoheptulose 7-phos-
phate (Fig.  3b). Together, these data suggest palbociclib 
decreases glucose metabolism through the PPP. Consist-
ent with our labeling data, palbociclib decreased glu-
cose 6-phosphate dehydrogenase (G6PD) activity in an 
RB-dependent manner (Fig.  3c). Additionally, we meas-
ured expression of G6PD and other genes within nucleo-
tide synthesis including phosphoribosyl pyrophosphate 
synthetase 2 (PRPS2) and ribonucleotide reductase 1/2 
(RRM1/2). Palbociclib decreased expression of RRM2 in 
an RB-dependent manner but does not significantly alter 
expression of these other genes within nucleotide synthe-
sis (Fig. 3d–g).
Palbociclib increases oxygen consumption in A549 cells
CDK4/6 inhibition has been reported to increase both 
mitochondrial mass and oxygen consumption in pan-
creatic cancer [14]. As such, we assessed mitochondrial 
activity by measurement of the oxygen consumption rate 
(OCR) in A549 cells following palbociclib treatment. 
Consistent with other cancer types [14, 15], we observed 
a significant increase in several parameters of mitochon-
drial activity including basal (p = 0.002) and non-mito-
chondrial respiration (p = 0.01) and ATP production 
(p = 0.034) (Fig. 4). While two-way ANOVA revealed no 
interaction between palbociclib treatment and RB sta-
tus (p = 0.113), palbociclib increased basal OCR 1.4-fold, 
which was reduced to 1.2-fold in the absence of RB.
To determine if the increase in basal oxygen con-
sumption upon palbociclib treatment is the result of 
a b
c d e f
Fig. 1 Palbociclib does not alter glucose uptake or glycolytic function in A549 cells. a Glucose uptake assessed by intracellular 2-[14C]-deoxyglucose 
in A549 cells following knockdown of RB and 48-h treatment with 1 μM palbociclib. b Glycolysis stress test measured in A549 cells following 
knockdown of RB and 48-h treatment with 1 μM palbociclib using a Seahorse XFe96 Analyzer. c–f ECAR assessment of c glycolytic capacity, d 
glycolytic reserve, e glycolysis, and f non-glycolytic acidification. Values represent mean ± SD, analyzed by two-way ANOVA with Sidak’s post hoc 
multiple comparisons (n = 3, independent experiments)
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increased glucose oxidation, we measured TCA cycle 
metabolites following [U-13C]-glucose labeling in A549 
cells. Pyruvate (m + 3) generated from glycolysis can be 
metabolized to lactate by lactate dehydrogenase (LDH) 
or oxidized in the TCA cycle through pyruvate dehy-
drogenase (PDH) or pyruvate carboxylase (PC). PDH 
entry of pyruvate carbon is indicated by m + 2 (1st 
turn)/m + 4 (2nd turn) isotopologues, while PC activ-
ity is observed by m + 3 isotopologue labeling of TCA 
intermediates (Fig.  5a). While there was no consistent 
effect on PDH-mediated pyruvate carbon entry (m + 2 
or m + 4), we found that palbociclib increased m + 3 
labeling of several TCA metabolites, suggesting palbo-
ciclib may increase PC activity for anaplerosis in A549 
cells (Fig. 5b–e).
Palbociclib sensitizes A549 cells to glutaminase inhibition 
in an RB‑dependent manner
We next sought to determine whether palbociclib alters 
the capacity to metabolize or the dependency on specific 
TCA fuels such as glucose, glutamine, or fatty acids for 
mitochondrial function using the Mito Fuel Flex assay on 
the Seahorse XFe96 analyzer. Palbociclib had no effect on 
the overall capacity of A549 cells to utilize glucose but 
did decrease the cells’ dependency on glucose to main-
tain basal respiration, indicating glucose is not the sole 
fuel source for the TCA cycle in palbociclib treated cells 
(Fig.  6a, d). While palbociclib increases the capacity to 
oxidize fatty acids, it has no effect on the cells’ depend-
ency for fatty acid oxidation, suggesting that inhibi-
tion of fatty acid oxidation would have no effect on the 
a b
c
d e f g
Fig. 2 Palbociclib does not alter glucose carbon incorporation into glycolytic intermediates in A549 cells. a Cartoon of [U-13C]-glucose fate 
mapping though glycolysis. Red circles indicate 13C. Fractional enrichment of m + 6 labeled b glucose 6-phosphate and c fructose 6-phosphate, 
and m + 3 labeled d 3-phosphoglycerate, e phosphoenolpyruvate, f pyruvate, and g lactate following 48-h treatment with 1 μM palbociclib. Values 
represent mean ± SD, analyzed by unpaired student’s t-test (n = 6, technical replicates)
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viability of palbociclib treated cells (Fig. 6b, e). Notably, 
we observed an increase in both glutamine capacity and 
dependency in A549 cells upon palbociclib treatment 
(Fig. 6c, f ).
The enzyme glutaminase converts glutamine to glu-
tamate and is highly expressed in cancer cells [26–28]. 
CB-839 is a highly potent glutaminase inhibitor that has 
shown anti-tumor activity in both in  vitro and in  vivo 
models of lung cancer [29]. We hypothesized that the 
observed increase in glutamine dependency may sensi-
tize palbociclib treated cells to glutaminase inhibition. 
Although palbociclib does not significantly alter glu-
taminase (GLS) gene expression (Fig.  6g), we observed 
a significant proliferative decrease in cells treated in 
combination with the glutaminase inhibitor CB-839 and 
palbociclib compared with palbociclib or CB-839 alone 
(Fig.  6h). Additionally, statistical analysis found a sig-
nificant interaction between inhibitor sensitivity and RB 
status (p < 0.0001), suggesting RB expression is necessary 
for palbociclib to exert its effect on glutamine depend-
ency. Together, our data highlight that palbociclib-
induced metabolic adaptations have the potential to be 
therapeutically exploited.
Discussion
While targeting cancer metabolism for therapeutic 
intervention has been extensively studied [30–34], 
there is a growing appreciation for cell cycle proteins 
that display metabolic regulatory functions [6, 35–38]. 
Additionally, with the increase in utilization of CDK4/6 
inhibitors in the clinic, there is a need for better under-
standing of the metabolic consequences of CDK4/6 
inhibition. In the current study, we report that activa-
tion of RB via treatment with the CDK4/6 inhibitor pal-
bociclib in A549 lung adenocarcinoma cells results in 
a metabolic shift wherein palbociclib alters aspects of 
a b c
d e f g
Fig. 3 Palbociclib decreases glucose carbon incorporation into PPP intermediates, in part, via decreased G6PD activity. a Fractional enrichment 
of m + 5 labeled nucleotides and nucleosides, and b m + 7 sedoheptulose 7-phosphate following 48-h treatment with 1 μM palbociclib. Values 
represent mean ± SD, analyzed by unpaired student’s t-test (n = 6, technical replicates). Statistical significances between each group are as follows: 
**p < 0.01 and ***p < 0.001. c G6PD activity assessed in A549 cells following knockdown of RB and 48-h treatment with 1 μM palbociclib. d–g qPCR 
analysis of glucose 6-phosphate dehydrogenase (G6PD), phosphoribosyl pyrophosphate synthetase 2 (PRPS2), and ribonucleotide reductase 1/2 
(RRM1/2) in A549 cells following knockdown of RB and 48-h treatment with 1 μM palbociclib. c–g Values represent mean ± SD, analyzed by two-way 
ANOVA with Sidak’s post hoc multiple comparisons (n = 3, independent experiments). Statistical significances between each group are as follows: 
**p < 0.01
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glucose and glutamine utilization. Specifically, palboci-
clib decreases glucose metabolism through the PPP via 
inhibition of G6PD activity (Fig.  3a–c), while increas-
ing glutaminolysis to maintain basal mitochondrial 
function (Fig. 6c, f ). Moreover, both changes observed 
were rescued upon knockdown of RB, suggesting the 
metabolic consequences of CDK4/6 inhibition in A549 
cells are RB-dependent.
Recently, it has been demonstrated that CDKs can 
directly regulate metabolism via phosphorylation of 
metabolic enzymes. Specifically, the cyclin D3/CDK6 
kinase complex can phosphorylate pyruvate kinase M2 
a
b c d
e f g
Fig. 4 Palbociclib increases mitochondrial respiration in A549 cells. a Oxygen consumption rate (OCR) measured in A549 cells following 
knockdown of RB and 48-h treatment with 1 μM palbociclib. b–g OCR assessment of b basal respiration, c non-mitochondrial respiration, d maximal 
respiration, e ATP production, f proton leak, and g spare capacity. Values represent mean ± SD, analyzed by two-way ANOVA (n = 3, independent 
experiments). Statistical significances between vehicle and palbociclib treatment are as follows: *p = 0.034, **p = 0.01, and ***p = 0.002
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and 6-phosphofructokinase [16]. The authors report this 
results in shunting of glycolytic intermediates into the 
PPP and the serine synthesis pathways, and treatment 
with palbociclib reduces this flux, resulting in NADPH 
and glutathione depletion and inducing apoptosis. We 
also observed a decrease in glucose carbon incorpora-
tion into nucleotides (Fig.  3a). This was in part due to 
decreased activity of the rate limiting enzyme in the PPP, 
G6PD (Fig.  3c). As A549 cells express both CDK4 and 
CDK6, it remains unclear whether the observed decrease 
in G6PD activity is due to the inhibitory effects of the 
cyclin D3/CDK6 complex.
As previously described, palbociclib increases mito-
chondrial activity in  vitro [14, 15]. Specifically, CDK4/6 
inhibition increases glutamine utilization and sensitivity 
to glutaminase inhibition in breast and colorectal cancer 
cells [15]. The authors reported that the increase in glu-
taminolysis was a result of enhanced MYC signaling in 
response to CDK4/6 inhibition. We did observe a modest 
increase in basal oxygen consumption upon palbociclib 
treatment (Fig. 4b), which is driven, in part, by enhanced 
glutaminolysis (Fig.  6c, f ). This sensitized A549 cells to 
treatment with CB-839 (Fig.  6h). MYC exerts its effect 
on glutaminolysis in part via upregulation of glutaminase 
[39, 40]. As we did not observe a significant increase in 
GLS expression (Fig. 6g), our data suggest the enhanced 
glutaminolysis in this context may be independent of 
MYC signaling.
While other studies have reported enhanced gly-
colysis upon CDK4/6 inhibition or deletion, or direct 
activation of RB itself [14, 15, 41], our [U-13C]-glucose 
and ECAR studies revealed no significant changes 
in glycolytic function upon palbociclib treatment 
(Figs.  1, 2). One possible explanation for this discrep-
ancy is the more acute treatment duration for our 
studies (48-h compared to 5–7  days). To address this, 
cells were treated with palbociclib for 5-days and, 
similar to 48-h exposure, we did not observe any dif-
ferences in glycolytic parameters within the glycoly-
sis stress test (Additional file  1: Figure S3). Prolonged 
CDK4/6 inhibition (96 h to 2 weeks) has been reported 
to induce both senescence and autophagy in vitro [14, 
15, 42, 43]. Many of the reported metabolic conse-
quences of longer-term palbociclib treatment are also 
metabolic hallmarks of these cellular processes. Senes-
cent cells exhibit elevated glycolysis and mitochondrial 
a b c
d e
Fig. 5 Palbociclib increases PC-mediated anaplerosis in A549 cells. a Cartoon of [U-13C]-glucose fate mapping through the 1st turn of the TCA 
cycle. Red circles are 13C labeling indicative of pyruvate dehydrogenase activity, green circles are 13C labeling indicative of pyruvate carboxylase 
activity, and white circles are unlabeled 12C. b–e Fractional enrichment of the TCA metabolites b citrate, c fumarate, d malate, and e aspartate in 
A549 cells following 48-h treatment with 1 μM palbociclib. Values represent mean ± SD, analyzed by unpaired student’s t-test for each metabolite 
isotopologue (vehicle vs. palbociclib) (n = 6, technical replicates). Statistical significances between each group are as follows: ***p < 0.001
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metabolism, resulting in increased mitochondrial mass 
and production of reactive oxygen species (ROS) [44, 
45]. This triggers autophagy and protein degradation 
to mitigate the cellular stress induced by senescence 
[46]. Recently, palbociclib-mediated induction of these 
cellular responses has been found to be dependent on 
both RB expression and lack of low molecular weight 
cyclin E (LMWE) [43]. As A549 cells express LMWE, 
this cell model is presumed to be resistant to senes-
cence or autophagy upon palbociclib treatment [43]. 
a b c
d e f
g h
Fig. 6 Palbociclib increases glutamine dependency and sensitizes A549 cells to glutaminase inhibition. a Glucose, b fatty acid, and c glutamine 
capacity, and d glucose, e fatty acid, and f glutamine dependency measured by the Mito Fuel Flex assay in A549 cells following 48-h treatment 
with 1 μM palbociclib. For (a–f), values represent mean ± SD, analyzed by unpaired student’s t-test (n = 3, independent experiments). Statistical 
significances between each group are as follows: *p < 0.05 and **p < 0.01. g qPCR analysis of glutaminase (GLS) following knockdown of RB and 48-h 
treatment with 1 μM palbociclib. h Cell proliferation following knockdown of RB and 48-h treatment with 1 μM palbociclib and/or 25 nM CB-839. 
For (g, h), values represent mean ± SD, analyzed by two-way ANOVA with Sidak’s post hoc multiple comparisons (n = 3, independent experiments). 
Statistical significances between each group are as follows: ***p < 0.001
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This may explain the lack of glycolytic changes in A549 
cells under prolonged exposure compared to other cell 
types [14, 15] and may need to be considered when 
assessing metabolic responses to palbociclib across dif-
ferent cancer models. Our studies are unique in that 
we have identified a metabolic response in A549 cells 
under shorter-term CDK4/6 inhibition.
Given the recent use of palbociclib in clinical trials for 
NSCLC patients, understanding the functional conse-
quences of CDK4/6 inhibition on cancer cell metabolism 
are important for identifying potential combination ther-
apies to improve patient outcome. Our studies in A549 
cells demonstrate that palbociclib treatment increases 
glutamine dependency and sensitizes cells to the glutam-
inase inhibitor, CB-839. While the precise mechanism 
by which palbociclib mediates increased glutaminolysis 
remains unclear, RB expression is required for palbociclib 
to exert its function in this context. A noted limitation to 
this work is that the analysis on the metabolic response 
to palbociclib is solely performed within the A549 cell 
line. Further work will not only be necessary to define 
the cellular mechanisms for these palbociclib effects but 
also required in additional models to more firmly estab-
lish these metabolic changes in response to drug treat-
ment across NSCLC in general. Our data highlight the 
metabolic changes upon palbociclib treatment in A549 
cells and may support the of targeting CDK4/6 inhibition 
in combination with glutaminase inhibitors in NSCLC 
patients with RB-proficient tumors.
Conclusions
Herein, we report that palbociclib treatments results in 
a metabolic shift in A549 cells. Specifically, we found 
that palbociclib decreases glucose metabolism through 
the PPP via inhibition of G6PD activity, while increas-
ing dependency on glutaminolysis to maintain basal 
mitochondrial function While the precise mechanism 
by which palbociclib mediates its metabolic functions 
remain unclear, its effect on glucose and glutamine uti-
lization in A549 cells are RB-dependent. Together, our 
data define the metabolic impact of CDK4/6 inhibition 
in a NSCLC cell type and highlight unique vulnerabilities 
that may be targeted using combination therapy with pal-
bociclib treatment.
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